Industry Briefs: December 3, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
AMRI will close its Bothell, Washington, site, and transition the site’s drug-discovery capabilities to Singapore while certain analytical capabilities will consolidate into the company’s analytical quality group in Albany, New York.
Aptiv Solutions has opened a new laboratory and office in Durham, North Carolina.
Bend Research, PATH, and Fraunhofer USA Center for Molecular Biotechnology (FhCMB) have developed a new technology for the production of thermostable vaccines.
biOasis Technologies has entered into a research collaboration agreement with UCB to evaluate biOasis’s Transcend technology in the area of the delivery of therapeutic compounds to the brain.
Capsugel has doubled its laboratory capacity with the opening of its new quality-control laboratory in Greenwood, South Carolina.
Covance’s early-development facility in Shanghai, China, has received a Good Laboratory Practice Certificate from China’s State Food and Drug Administration.
Dalton Pharma Services has added size-exclusion chromatography (SEC) - multi angle (laser) light-scattering (MALS) large-molecule testing services.
Galena Biopharma has signed an agreement with a subsidiary of Teva Pharmaceutical Industries for the commercialization of NeuVax (nelipepimut-S or E75) in Israel.
Hovione and Solvias have announced a collaboration focused on the development and GMP supply of pharmaceutical cocrystals.
NextPharma has completed the sale of its Bioserv, its US affiliate, to KESA Partners.
Noven Pharmaceuticals has acquired commercial rights to Minivelle (estradiol transdermal system) in the US and Canada.
Recipharm has invested to expand its capacity in analytical services and stability studies at its facility in Solna, Sweden.
Single Cell Technology and Open Monoclonal Technology have announced a human antibody discovery and development collaboration.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
